← SynDRA
SAR-260301
SynDRA canonical compound SYN0037816 — structure-anchored drug synonym record
| Clinical phase | Phase 1 |
|---|
| Primary target(s) | PIK3C2G | PIK3C3 | PIK3CA | PIK3CB | PIK3CD |
|---|
| Mechanism of action | pi3k inhibitor |
|---|
| Indication | melanoma |
|---|
| Disease area | oncology |
|---|
All known targets
- PIK3CB
- PIK3C2G
- PIK3C3
- PIK3CA
- PIK3CD
Mechanisms of action (all sources)
- PIK3CB INHIBITOR
- PI3-kinase p110-beta subunit inhibitor
- PIK3C3 INHIBITOR
- PIK3CA INHIBITOR
- PIK3CD INHIBITOR
- PIK3C2G INHIBITOR
- PI3K inhibitor
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- PIK3CG
- PRKDC
- AKT1
- CYP3A4
- MTOR
- PIK3C2A
- PIK3C2B
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
Cross-references
Synonyms
- SAR260301
- RefChem:181306
- PI3K-beta Inhibitor SAR260301
- MFCD27987912
- compound 28 [PMID: 24387221]
- 4bfr
- UAXHPOBBKRWJGA-ZDUSSCGKSA-N
- J82
- UNII-33639WNC7Q
- GTPL8793
- orb1307758
- SCHEMBL1027765
- GLXC-15264
- KAC61213
- AKOS025291099
- AKOS040742610
- AS-35206
- DA-77684
- HY-15837
- CS-0009322
- SCHEMBL1030955
- NSC-780290
- SB16716
- SCHEMBL22595038
- NSC780291
- UAXHPOBBKRWJGA-UHFFFAOYSA-N
- DB-192277
- BDBM50447100
- SCHEMBL1030883
- NSC780290
- NSC-780291
Look up SAR-260301 in the interactive SynDRA portal →